Gynecologic Oncology

February 10, 2021 - A biologics license application has been submitted to the FDA for the accelerated approval of the antibody-drug conjugate tisotumab vedotin for use in patients with recurrent or metastatic cervical cancer that has progressed on or following chemotherapy.

Dr. Markman discusses the clinical milestone of the HPV vaccine as a means to prevent cervical cancer, the debate on HPV-negative disease, and what efforts can be done on a global scale to reduce the incidence and mortality of cervical cancer.

Robert L. Coleman, MD, FACOG, FACS, discusses the potential of tisotumab vedotin in cervical cancer.

The idea that HPV-negative cervical cancer is possible, especially in a disease that is mainly driven by HPV positivity, is not a unanimous opinion.

Maurie Markman, MD, discusses remaining questions regarding human papillomavirus–negative cervical cancer.

Robert L. Coleman, MD, FACOG, FACS, discusses the potential to move immunotherapy into earlier lines of treatment in cervical cancer.

Joshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in ovarian cancer, remaining questions regarding repeat inhibition and treatment duration, and the potential for combinations.

January 6, 2021 — The oral small molecule inhibitor VS-6766, developed by Verastem Oncology, is now under investigation alone and in combination with the FAK inhibitor defactinib in a recently initiated, registration-directed, phase 2 trial in patients with recurrent low-grade serous ovarian cancer.

January 5, 2020 - Boehringer Ingelheim will add to its cancer cell-directed therapies portfolio with the acquisition of NBE-Therapeutics, the developer of NBE-002, an anti-ROR1 antibody-drug conjugate.

Bradley Corr, MD, discusses the rationale to evaluate WNT pathway inhibition in gynecologic cancers.